NCT01763164 is a Phase 3 clinical trial of MEK162 in Metastatic or Unresectable Cutaneous Melanoma, sponsored by Pfizer.

Who is sponsoring NCT01763164?

NCT01763164 is sponsored by Pfizer.

What drugs are being tested in NCT01763164?

Interventions in NCT01763164: MEK162, Dacarbazine.

What condition does NCT01763164 study?

NCT01763164 studies Metastatic or Unresectable Cutaneous Melanoma.

Is NCT01763164 still recruiting?

NCT01763164 is currently completed. Last updated 22 March 2021.

Are results published for NCT01763164?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-03-22 · How we verify

NCT01763164

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Completed Phase 3 Results posted Last updated 22 March 2021

What this trial tests

Phase 3 trial testing MEK162 in Metastatic or Unresectable Cutaneous Melanoma in 402 participants. Completed in 4 June 2019.

Timeline

12 July 2013

Primary endpoint
1 December 2015

4 June 2019

Quick facts

Lead sponsor	Pfizer
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	402
Start date	12 July 2013
Primary completion	1 December 2015
Estimated completion	4 June 2019
Sites	229 locations across Italy, Japan, Poland, South Korea, Netherlands, Russia, Belgium, Sweden

Drugs / interventions tested

MEK162 (mek162) — full drug profile →
Dacarbazine (dacarbazine) — full drug profile →

Conditions studied

Metastatic or Unresectable Cutaneous Melanoma — all drugs for Metastatic or Unresectable Cutaneous Melanoma →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Metastatic or Unresectable Cutaneous Melanoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Primary · From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)

PFS: time from randomization to first documented PD or death due to any cause, whichever occurred first. RECIST 1.1, PD: \>=20% increase in sum of diameter of target lesions (TLs) taking as reference the smallest sum on study (including baseline sum), sum must also be an absolute increase of \>=5 mm; unequivocal progression of existing non-TLs; appearance of \>=1 lesion. Complete response (CR): disappearance of all lesions; any pathological lymph nodes (TLs) or non-pathological (non-TLs) must have reduction in short axis to \<10 mm; normalization of tumor marker level for non-TLs. Partial resp

Group	Value	95% CI
Binimetinib (MEK162)	2.83	2.76 – 3.55
Dacarbazine	1.51	1.48 – 1.71

Overall Survival (OS) Secondary · From the date of randomization to the date of death (maximum up to 107 weeks for binimetinib arm; maximum up to 88 weeks for dacarbazine arm)

Overall survival was defined as the time from the date of randomization to the date of death due to any cause. If a participant was not known to have died, overall survival was censored at the date of last known date participant alive.

Group	Value	95% CI
Binimetinib (MEK162)	10.97	8.94 – 13.60
Dacarbazine	10.09	7.03 – 16.46

Overall Response Rate (ORR) Secondary · From date of randomization until first documented response of CR or PR (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)

ORR: percentage of participants with best overall response (BOR) of CR or PR. BOR: best response recorded from start of treatment until CR or PR. RECIST V1.1, a) CR: disappearance of all lesions; any pathological lymph nodes (TLs) or non-pathological (non-TLs) must have reduction in short axis to \<10 mm; normalization of tumor marker level for non-TLs; b) PR: \>=30% decrease in sum of diameter of all TLs, taking as reference baseline sum of diameters. ORR is reported for confirmed and unconfirmed responses. Confirmed CR or PR = at least 2 determinations of CR or PR at least 4 weeks apart befo

Confirmed ORR

Group	Value	95% CI
Binimetinib (MEK162)	15.2	11.2 – 20.1
Dacarbazine	6.8	3.1 – 12.5

Confirmed + Unconfirmed: ORR

Group	Value	95% CI
Binimetinib (MEK162)	22.7	17.8 – 28.2
Dacarbazine	9.8	5.3 – 16.1

Time to Response (TTR) Secondary · From date of randomization until first documented response of CR or PR (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)

TTR: time between date of randomization until first documented response of CR or PR. RECIST V1.1, a) CR: disappearance of all lesions; any pathological lymph nodes (TLs) or non-pathological (non-TLs) must have reduction in short axis to \<10 mm; normalization of tumor marker level for non-TLs; b) PR: \>=30% decrease in sum of diameter (dia) of all TLs, referring baseline sum of dia; c) PD: \>=20% increase in sum of diameter of all measured TLs taking as reference smallest sum of diameter of all TLs recorded at or after baseline, sum must also be absolute increase of \>=5 mm. Unequivocal progre

Group	Value	95% CI
Binimetinib (MEK162)	1.45	1.45 – 1.48
Dacarbazine	2.79	1.22 – 3.38

Duration of Objective Response (DOR) Secondary · From the date of first documented response (CR or PR) to the first documented progression or death (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)

DOR: time from date of first documented response (CR or PR) to first documented progression or death due to underlying cancer. RECIST V1.1, a) CR: disappearance of all lesions; any pathological lymph nodes (TLs) or non-pathological (non-TLs) must have reduction in short axis to \<10 mm; normalization of tumor marker level for non-TLs; b) PR: \>=30% decrease in sum of diameter (dia) of all TLs, referring baseline sum of dia; c) PD: \>=20% increase in sum of diameter of all measured target lesions taking as reference smallest sum of diameter of all target lesions recorded at or after baseline, s

Group	Value	95% CI
Binimetinib (MEK162)	6.87	4.21 – 11.07
Dacarbazine	NA	4.14 – NA

Disease Control Rate (DCR) Secondary · From date of randomization until first documented response of CR, PR, SD or non-CR/non-PD (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)

DCR was calculated as the percentage of participants with a BOR of CR, PR, SD RECIST V1.1, a) CR: disappearance of all lesions; any pathological lymph nodes (TLs) or non-pathological (non-TLs) must have reduction in short axis to \<10 mm; normalization of tumor marker level for non-TLs; b) PR: \>=30% decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters; c) SD: neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD taking as reference the smallest sum diameters; d) PD: \>=20% increase in sum of d

Group	Value	95% CI
Binimetinib (MEK162)	58.4	52.2 – 64.3
Dacarbazine	24.8	17.7 – 33.0

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Secondary · From baseline up to 219.4 weeks for binimetinib arm; From baseline up to 123.9 weeks for dacarbazine arm

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with the study treatment. SAE was defined as one of the following: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. Treatment-emergent AE was defined as an AE with onset date occurring during the on-treatment period. AEs included all SAEs and non-SAEs.

AEs

Group	Value	95% CI
Binimetinib (MEK162)	269
Dacarbazine	104

SAEs

Group	Value	95% CI
Binimetinib (MEK162)	95
Dacarbazine	26

Number of Participants With Clinically Notable Hematology Shifts Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Grade, Version 4.03 Secondary · From baseline up to 77 weeks in binimetinib arm; From baseline up to 61 weeks for dacarbazine arm

Clinically notable shifts are defined as worsening by at least 2 grades or to \>= grade 3. Severity was graded as Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent in

Activated partial thromboplastin time prolonged

Group	Value	95% CI
Binimetinib (MEK162)	7
Dacarbazine	2

Hemoglobin decreased

Group	Value	95% CI
Binimetinib (MEK162)	17
Dacarbazine	13

Prothrombin international normalized ratio increased

Group	Value	95% CI
Binimetinib (MEK162)	9
Dacarbazine	0

Lymphocytes increased

Group	Value	95% CI
Binimetinib (MEK162)	20
Dacarbazine	0

Lymphocytes decreased

Group	Value	95% CI
Binimetinib (MEK162)	35
Dacarbazine	19

Neutrophils decreased

Group	Value	95% CI
Binimetinib (MEK162)	8
Dacarbazine	21

Platelets decreased

Group	Value	95% CI
Binimetinib (MEK162)	3
Dacarbazine	17

Leukocytes increased

Group	Value	95% CI
Binimetinib (MEK162)	0
Dacarbazine	0

Number of Participants With Clinically Notable Clinical Chemistry/Biochemistry Shifts Based on NCI-CTCAE Grade, Version 4.03 Secondary · From baseline up to 77 weeks in binimetinib arm; From baseline up to 61 weeks for dacarbazine arm

Clinically notable shifts are defined as worsening by at least 2 grades or to \>= grade 3. Severity was graded as Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade

Albumin decreased

Group	Value	95% CI
Binimetinib (MEK162)	27
Dacarbazine	5

Alkaline phosphatase

Group	Value	95% CI
Binimetinib (MEK162)	8
Dacarbazine	2

Alanine aminotransferase

Group	Value	95% CI
Binimetinib (MEK162)	14
Dacarbazine	4

Aspartate aminotransferase

Group	Value	95% CI
Binimetinib (MEK162)	20
Dacarbazine	1

Bilirubin

Group	Value	95% CI
Binimetinib (MEK162)	1
Dacarbazine	1

Corrected Calcium increased

Group	Value	95% CI
Binimetinib (MEK162)	2
Dacarbazine	4

Corrected Calcium decreased

Group	Value	95% CI
Binimetinib (MEK162)	2
Dacarbazine	0

Creatinine

Group	Value	95% CI
Binimetinib (MEK162)	9
Dacarbazine	2

Number of Participants With Clinically Notable Vital Signs Secondary · From baseline up to 77 weeks in binimetinib arm; From baseline up to 61 weeks for dacarbazine arm

Abnormalities criteria included: low/high pulse rate (beats per minute \[bpm\]):\<=50bpm with decrease from baseline \>=15bpm/\>=120bpm with increase from baseline \>=15bpm; Low/high systolic blood pressure (millimeters of mercury \[mmHg\]): \<=90mmHg with decrease from baseline \>=20mmHg/\>=160mmHg with increase from baseline \>=20mmHg; Low/high diastolic blood pressure \[mmHg\]: \<=50mmHg with decrease from baseline \>=15mmHg/\>=100mmHg with increase from baseline \>=15mmHg; Low/high body weight (kilogram \[kg\]): \>=20% decrease from baseline / \>=10% increase from baseline; Low/high body t

Sitting Pulse Rate - High

Group	Value	95% CI
Binimetinib (MEK162)	4
Dacarbazine	1

Sitting Pulse Rate - Low

Group	Value	95% CI
Binimetinib (MEK162)	3
Dacarbazine	1

Sitting systolic blood pressure - High

Group	Value	95% CI
Binimetinib (MEK162)	43
Dacarbazine	8

Sitting systolic blood pressure -Low

Group	Value	95% CI
Binimetinib (MEK162)	2
Dacarbazine	4

Sitting diastolic blood pressure - High

Group	Value	95% CI
Binimetinib (MEK162)	28
Dacarbazine	4

Sitting diastolic blood pressure - Low

Group	Value	95% CI
Binimetinib (MEK162)	2
Dacarbazine	1

Weight - High

Group	Value	95% CI
Binimetinib (MEK162)	16
Dacarbazine	1

Weight - Low

Group	Value	95% CI
Binimetinib (MEK162)	0
Dacarbazine	0

Number of Participants With Notable Electrocardiogram (ECG) Values Secondary · From baseline up to 77 weeks in binimetinib arm; From baseline up to 61 weeks for dacarbazine arm

Criteria for notable ECG values were as follow: QT interval (in millisecond \[msec\]) new (newly occurring post-baseline value) greater than (\>) 450, 480, 500, increase from baseline \>30, increase from baseline \>60; corrected QT interval by Fredericia formula (QTcF) in msec new (newly occurring post-baseline value) \> 450, 480, 500, increase from baseline \>30, increase from baseline \>60; corrected QT interval by Bazett's formula (QTcB) in msec new (newly occurring post-baseline value) \> 450, 480, 500, increase from baseline \>30, increase from baseline \>60; heart rate in bpm new (newly

QT - New > 450 msec

Group	Value	95% CI
Binimetinib (MEK162)	32
Dacarbazine	8

QT - New > 480 msec

Group	Value	95% CI
Binimetinib (MEK162)	7
Dacarbazine	1

QT - New > 500 msec

Group	Value	95% CI
Binimetinib (MEK162)	5
Dacarbazine	0

QT - Increase from baseline > 30 msec

Group	Value	95% CI
Binimetinib (MEK162)	109
Dacarbazine	33

QT - Increase from baseline > 60 msec

Group	Value	95% CI
Binimetinib (MEK162)	28
Dacarbazine	5

QTcF - New > 450 msec

Group	Value	95% CI
Binimetinib (MEK162)	29
Dacarbazine	15

QTcF - New > 480 msec

Group	Value	95% CI
Binimetinib (MEK162)	10
Dacarbazine	1

QTcF - New > 500 msec

Group	Value	95% CI
Binimetinib (MEK162)	5
Dacarbazine	1

Number of Participants With Adverse Events of Special Interest: Cardiac Events Secondary · From baseline up to 77 weeks in binimetinib arm; From baseline up to 61 weeks for dacarbazine arm

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with the study treatment. Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL;

Group	Value	95% CI
Binimetinib (MEK162)	35
Dacarbazine	2

Adverse events — posted to ClinicalTrials.gov

Time frame: From baseline up to 219.4 weeks for binimetinib arm; From baseline up to 123.9 weeks for dacarbazine arm. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Binimetinib (MEK162)

Serious: 95/269 (35%)

Deaths: —

Dacarbazine

Serious: 26/114 (23%)

Deaths: —

Serious adverse events (129 terms)

Reaction	System	Binimetinib (MEK162)	Dacarbazine
GENERAL PHYSICAL HEALTH DETERIORATION	General disorders	—	—
RETINAL VEIN OCCLUSION	Eye disorders	—	—
PULMONARY EMBOLISM	Respiratory, thoracic and mediastinal disorders	—	—
VOMITING	Gastrointestinal disorders	—	—
PYREXIA	General disorders	—	—
SKIN INFECTION	Infections and infestations	—	—
BLOOD CREATINE PHOSPHOKINASE INCREASED	Investigations	—	—
DYSPNOEA	Respiratory, thoracic and mediastinal disorders	—	—
PNEUMONITIS	Respiratory, thoracic and mediastinal disorders	—	—
ANAEMIA	Blood and lymphatic system disorders	—	—
PANCYTOPENIA	Blood and lymphatic system disorders	—	—
DIARRHOEA	Gastrointestinal disorders	—	—
MUSCULAR WEAKNESS	Musculoskeletal and connective tissue disorders	—	—
RENAL FAILURE	Renal and urinary disorders	—	—
HYPERTENSIVE CRISIS	Vascular disorders	—	—
RETINAL VEIN THROMBOSIS	Eye disorders	—	—
CONSTIPATION	Gastrointestinal disorders	—	—
NAUSEA	Gastrointestinal disorders	—	—
CELLULITIS	Infections and infestations	—	—
ERYSIPELAS	Infections and infestations	—	—
PYELONEPHRITIS ACUTE	Infections and infestations	—	—
SEPSIS	Infections and infestations	—	—
SOFT TISSUE INFECTION	Infections and infestations	—	—
UROSEPSIS	Infections and infestations	—	—
INTERVERTEBRAL DISC PROTRUSION	Musculoskeletal and connective tissue disorders	—	—

Other adverse events (58 terms — click to expand)

Reaction	System	Binimetinib (MEK162)	Dacarbazine
BLOOD CREATINE PHOSPHOKINASE INCREASED	Investigations	—	—
DIARRHOEA	Gastrointestinal disorders	—	—
DERMATITIS ACNEIFORM	Skin and subcutaneous tissue disorders	—	—
OEDEMA PERIPHERAL	General disorders	—	—
RASH	Skin and subcutaneous tissue disorders	—	—
NAUSEA	Gastrointestinal disorders	—	—
FATIGUE	General disorders	—	—
VOMITING	Gastrointestinal disorders	—	—
ASTHENIA	General disorders	—	—
CONSTIPATION	Gastrointestinal disorders	—	—
ASPARTATE AMINOTRANSFERASE INCREASED	Investigations	—	—
DRY SKIN	Skin and subcutaneous tissue disorders	—	—
HYPERTENSION	Vascular disorders	—	—
RETINAL DETACHMENT	Eye disorders	—	—
EJECTION FRACTION DECREASED	Investigations	—	—
PYREXIA	General disorders	—	—
DECREASED APPETITE	Metabolism and nutrition disorders	—	—
EYELID OEDEMA	Eye disorders	—	—
MYALGIA	Musculoskeletal and connective tissue disorders	—	—
DYSPNOEA	Respiratory, thoracic and mediastinal disorders	—	—
PRURITUS	Skin and subcutaneous tissue disorders	—	—
SKIN FISSURES	Skin and subcutaneous tissue disorders	—	—
ABDOMINAL PAIN	Gastrointestinal disorders	—	—
ALOPECIA	Skin and subcutaneous tissue disorders	—	—
ALANINE AMINOTRANSFERASE INCREASED	Investigations	—	—
RASH MACULO-PAPULAR	Skin and subcutaneous tissue disorders	—	—
DRY MOUTH	Gastrointestinal disorders	—	—
NEUTROPENIA	Blood and lymphatic system disorders	—	—
DYSGEUSIA	Nervous system disorders	—	—
VISION BLURRED	Eye disorders	—	—
COUGH	Respiratory, thoracic and mediastinal disorders	—	—
ANAEMIA	Blood and lymphatic system disorders	—	—
SUBRETINAL FLUID	Eye disorders	—	—
INTRAOCULAR PRESSURE INCREASED	Investigations	—	—
BACK PAIN	Musculoskeletal and connective tissue disorders	—	—
ARTHRALGIA	Musculoskeletal and connective tissue disorders	—	—
HEADACHE	Nervous system disorders	—	—
RASH PUSTULAR	Infections and infestations	—	—
THROMBOCYTOPENIA	Blood and lymphatic system disorders	—	—
MACULAR OEDEMA	Eye disorders	—	—

Most-reported serious reactions: GENERAL PHYSICAL HEALTH DETERIORATION, RETINAL VEIN OCCLUSION, PULMONARY EMBOLISM, VOMITING, PYREXIA, SKIN INFECTION, BLOOD CREATINE PHOSPHOKINASE INCREASED, DYSPNOEA.

Data from ClinicalTrials.gov NCT01763164 adverse events section.

Sponsor's own description

Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive cutaneous or unknown primary melanoma. The mutation analysis will be performed at a central laboratory. Only those patients with Q61 mutation per central laboratory and meet all eligibility criteria will be randomized. A total of 393 patients will be randomized 2:1 to receive either MEK162 or dacarbazine. Patients will be stratified according to AJCC stage (IIIC, IVM1a, and IVM1b versus IVM1c), ECOG Performance status (0 versus 1) and any prior number of lines of immunotherapy (immunotherapies versus none). This study will use an Interactive Response Technology (IRT). The primary end point of the study is progression-free survival. Key secondary end point is overall survival

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

RAS-targeted therapies: is the undruggable drugged?
Moore AR, Rosenberg SC, McCormick F, Malek S. · · 2020 · cited 832× · PMID 32528145 · DOI 10.1038/s41573-020-0068-6
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Dummer R, Schadendorf D, Ascierto PA, Arance A, et al · · 2017 · cited 357× · PMID 28284557 · DOI 10.1016/s1470-2045(17)30180-8
Current Development Status of MEK Inhibitors.
Cheng Y, Tian H. · · 2017 · cited 181× · PMID 28954413 · DOI 10.3390/molecules22101551
Systemic treatments for metastatic cutaneous melanoma.
Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, et al · · 2018 · cited 140× · PMID 29405038 · DOI 10.1002/14651858.cd011123.pub2
Targeting the ERK Signaling Pathway in Melanoma.
Savoia P, Fava P, Casoni F, Cremona O. · · 2019 · cited 137× · PMID 30934534 · DOI 10.3390/ijms20061483
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
Wu PK, Park JI. · · 2015 · cited 107× · PMID 26615130 · DOI 10.1053/j.seminoncol.2015.09.023
Treatment of NRAS-mutant melanoma.
Johnson DB, Puzanov I. · · 2015 · cited 103× · PMID 25796376 · DOI 10.1007/s11864-015-0330-z
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, et al · · 2017 · cited 87× · PMID 28152546 · DOI 10.1038/bjc.2017.10

Verify or expand the search:

Other trials of MEK162

Trials testing the same drug.

NCT03158103 — A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumo · Phase 1 · completed
NCT02631447 — Sequential Combo Immuno and Target Therapy (SECOMBIT) Study · Phase 2 · completed
NCT02285439 — Study of MEK162 for Children With Low-Grade Gliomas · Phase 1, PHASE2 · completed
NCT02276027 — A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advance · Phase 2 · completed
NCT02159066 — LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma · Phase 2 · completed

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01763164 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 22 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01763164.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing